The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented exciting data on the use of ibrutinib for relapsed mantle cell lymphoma (MCL) from three clinical trials. In this interview, Graham Collins, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the striking results found for progression-free survival. Dr Collins highlights how this data may be translated into clinical use and change the standard of care for this group.
BTK inhibitors for relapsed mantle cell lymphoma: the new standard of care?
